| Literature DB >> 33639667 |
Ratnakar Shukla1, Pooja Shukla1, Anu Behari1, Dheeraj Khetan2, Rajendra K Chaudhary2, Yasuo Tsuchiya3, Toshikazu Ikoma3, Takao Asai4, Kazutoshi Nakamura3, Vinay K Kapoor1.
Abstract
BACKGROUND: Typhoid (Salmonella typhi and paratyphi) carriers and gall bladder cancer (GBC) are endemic in northern India. Results of previous studies about association of typhoid carriers with GBC are inconsistent. We studied antibodies against Salmonella typhi and paratyphi in serum samples of patients with GBC.Entities:
Keywords: Gall bladder cancer; Gall stone; Modified Widal test; Salmonella paratyphi; Salmonella typhi
Year: 2021 PMID: 33639667 PMCID: PMC8190372 DOI: 10.31557/APJCP.2021.22.2.509
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Gender-Wise Distribution of Cases Positive for Salmonella Infections
| GBC | XGC | CC | HC | OR (95% CI) among different groups | AOR (95% CI) | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Positive No. (%) | No. | Positive No. (%) | No. | Positive No. (%) | No. | Positive No. (%) | |||||
| Female | 74 | 12 (16) | 11 | 2 (18) | 125 | 30 (24) | 9 | 0 | GBC vs. HC | 3.8 (0.2-69.7) | 0.24 | |
| Male | 26 | 10 (38) | 13 | 5 (38) | 75 | 21 (28) | 191 | 5 (3) | GBC vs. HC | 23.3 (7.1-76.4) | < 0.001* | |
| Total | 100 | 22 (22) | 24 | 7 (29) | 200 | 51 (26) | 200 | 5 (3) | GBC vs. HC | 11.0 (4.0-30.1) | 0.0 (0.0-0.0) | < 0.001* |
CC, Chronic cholecystitis; GBC, Gall bladder cancer; HC, Healthy controls; XGC, Xanthogranulomatous cholecystitis
Positive Infection Rates of Salmonella in Cases and Controls in the Age Groups of <50 Years and ≥50 Years
| GBC | XGC | CC | HC | Comparisons among different groups | *P-value among subgroups | Overall *P-value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total No. | Positive No./Total No. (%) | Total No. | Positive No./Total No. (%) | Total No. | Positive No./Total No. (%) | Total No. | Positive No./Total No. (%) | ||||||||
| <50 Years | ≥50 Years | <50 Years | ≥50 Years | <50 Years | ≥50 Years | <50 Years | ≥50 Years | ||||||||
| Female | 74 | 5/31 (16) | 7/43 (16) | 11 | 2/6 (33) | 0/5 | 125 | 17/79 (22) | 13/46 (28) | 9 | 0/8 | 0/1 | GBC vs. HC | NA | 0.28 |
| Male | 26 | 1/7 (14) | 9/19 (47) | 13 | 0/3 | 5/10 (50) | 75 | 15/47 (32) | 6/28 (21) | 191 | 5/186 (3) | 0/5 | GBC vs. HC | 0.001 | <0.001 |
| Total | 100 | 6/38 (16) | 16/62 (26) | 24 | 2/9 (22) | 5/15 (33) | 200 | 32/126 (25) | 19/74 (26) | 200 | 5/194 (3) | 0/6 | GBC vs. HC | 0.003 | 0.003 |
CC, Chronic cholecystitis; GBC, Gall bladder cancer; HC, Healthy controls; XGC, Xanthogranulomatous cholecystitis; *Chi-square test was used; NA, Not applicable as there is no positive case in HC
Frequency of Serum Antibodies against Salmonella Typhi (Vi and O) and Salmonella Paratyphi (AO and BO) in Cases and Controls
| GBC | XGC | CC | HC | Comparisons among different groups | OR | 95% CI | *P-value among different subgroups | Overall *P-value | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Positive | No. | Positive | No. | Positive | No. | Positive | ||||||||||||||||||
|
| |||||||||||||||||||||||||
| Male | 26 | 6 (23)a | 13 | 0 | 75 | 14 (19) | 191 | 3 (2) | GBC vs. HC | 18.8 | 4.4-81.0 | < 0.001 | < 0.001 | ||||||||||||
| Female | 74 | 7 (9) | 11 | 2 (18) | 124 | 16 (13) | 9 | 0 | GBC vs. HC | 2.1 | 0.1-40.1 | 0.33 | 0.54 | ||||||||||||
| Total | 100 | 13 (13)a | 24 | 2 (8)b | 200 | 30 (15) | 200 | 3 (2) | GBC vs. HC | 9.8 | 2.7-35.3 | < 0.001 | < 0.001 | ||||||||||||
|
| |||||||||||||||||||||||||
| Male | 26 | 3 (12)a,c | 13 | 1 (8) | 75 | 1 (1) | 191 | 2 (1) | GBC vs. HC | 12.3 | 1.9-77.7 | 0.001 | 0.004 | ||||||||||||
| Female | 74 | 5 (7) | 11 | 1 (9) | 125 | 6 (5) | 9 | 0 | GBC vs. HC | 1.5 | 0.1-29.4 | 0.42 | 0.75 | ||||||||||||
| Total | 100 | 8 (8)a | 24 | 2 (8)b | 200 | 7 (3) | 200 | 2 (1) | GBC vs. HC | 8.6 | 1.7-41.3 | 0.001 | 0.012 | ||||||||||||
| O antibody for | |||||||||||||||||||||||||
| Male | 26 | 2 (8)a | 13 | 2 (15) b | 75 | 10 (13) | 191 | 0 | GBC vs. HC | 39.1 | 1.8-838 | 0.001 | < 0.001 | ||||||||||||
| GBC | XGC | CC | HC | Comparisons among different groups | OR | 95% CI | *P-value among different subgroups | Overall *P-value | |||||||||||||||||
| No. | Positive No. (%) | No. | Positive No. (%) | No. | Positive No. (%) | No. | Positive No. (%) | ||||||||||||||||||
| O antibody for | |||||||||||||||||||||||||
| Female | 74 | 4 (5) | 11 | 0 | 125 | 10 (8) | 9 | 0 | GBC vs. HC | 1.2 | 0.1-24.4 | 0.47 | 0.57 | ||||||||||||
| Total | 100 | 6 (6)a | 24 | 2 (8)b | 200 | 20 (10) | 200 | 0 | GBC vs. HC | 27.5 | 1.5-495 | 0.001 | 0.001 | ||||||||||||
| O antibody for | |||||||||||||||||||||||||
| Male | 26 | 3 (8)a | 13 | 2 (15) b | 75 | 5 (7) | 191 | 0 | GBC vs. HC | 57 | 2.9-1140 | <0.001 | 0.001 | ||||||||||||
| Female | 74 | 1 (1) | 11 | 1 (9) | 125 | 6 (5) | 9 | 0 | GBC vs. HC | 0.4 | 0.0-10.2 | 0.73 | 0.42 | ||||||||||||
| Total | 100 | 4 (4)a | 24 | 3 (12)b | 200 | 11(5) | 200 | 0 | GBC vs. HC | 18.7 | 0.9-351 | 0.004 | 0.001 | ||||||||||||
CC, Chronic cholecystitis ; GBC, Gall bladder cancer; HC, Healthy controls ; XGC, Xanthogranulomatous cholecystitis;*Chi-square test was used; OR, Odds ratio; NA, Not applicable as there is no positive case in XGC vs. HC; aP <0.01 between GBC vs. HC; bP <0.05 between XGC vs. HC; cP <0.05 between GBC vs. CC